Feasibility study of 21-day-on/7-day-off temozolomide in children with brain tumors.
Temozolomide (TMZ) is an oral alkylating agent with proven antitumoral activity in preclinical and clinical studies in adults with high-grade glioma (HGG). However, only limited efficacy has been reported in children with HGG using the 5-day schedule. This study investigated the safety of administering TMZ to children and adolescents with brain tumors over an extended period. Extended schedules have been proven to overcome chemoresistance without any major toxicity. The toxicity of TMZ, administered at 70 mg/m(2)/day orally for 21 consecutive days every 28 days, was assessed in children with brain tumors. A total of 156 courses of TMZ were given to 17 patients (median age 12.5 years, range 1-17 years), who were recruited into the study. Eleven patients had progressive or relapsing disease, and six patients were newly diagnosed. In this cohort no cases of toxic death or nonhematological toxicity were reported. In comparison with the 5-day schedule, thrombocytopenia and neutropenia were noted to be less frequent. Grades 3 and 4 lymphopenia occurred in 10.8 and 22.4% of courses, respectively; among the lymphopenic patients there was one case of disseminated zoster (meningoencephalitis and cutaneous involvement), one case of rotavirus gastroenteritis, and two cases of herpetic stomatitis reported. The objective response rate was 11.8%. Overall, 82.3% of patients showed stable disease. The prolonged TMZ schedule appeared to be well tolerated, with few cases of neutropenia or thrombocytopenia recorded. Nevertheless, prolonged exposure to TMZ was associated with lymphopenia and may lead to a higher rate of viral infections.
Ridola
Vita
V
Department of Pediatric Oncology, A. Gemelli Hospital, Catholic University of Rome, Largo A Gemelli 1, 00168 Rome, Italy. vita.ridola@rm.unicatt.it
Barone
Giuseppe
G
Lazzareschi
Ilaria
I
Ruggiero
Antonio
A
Rizzo
Daniela
D
Riccardi
Riccardo
R
D000293:Adolescent; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D018450:Disease Progression; D004334:Drug Administration Schedule; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D005910:Glioma / Q000188:drug therapy* / Q000556:secondary; D006801:Humans; D007223:Infant; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology; D015996:Survival Rate; D000077204:Temozolomide; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide
Cancer Res. 1998 Oct 1;58(19):4363-7
9766665
Br J Cancer. 1992 Feb;65(2):287-91
1739631
J Pharmacol Exp Ther. 2007 Apr;321(1):265-75
17259446
Br J Cancer. 2004 Aug 2;91(3):425-9
15266331
Oncol Rep. 2006 Nov;16(5):1117-21
17016602
Neoplasma. 2002;49(2):117-20
12088104
J Clin Oncol. 2002 Mar 1;20(5):1375-82
11870182
J Clin Oncol. 1999 Sep;17(9):2762-71
10561351
J Neurooncol. 2009 Oct;95(1):13-22
19381445
J Clin Oncol. 2002 Dec 15;20(24):4684-91
12488414
N Engl J Med. 2005 Mar 10;352(10):987-96
15758009
Br J Cancer. 2003 Apr 7;88(7):1004-11
12671695
Eur J Cancer. 2006 Sep;42(14):2335-42
16899365
Pediatr Blood Cancer. 2007 Nov;49(6):808-11
17588234
Nat Clin Pract Oncol. 2006 Jun;3(6):339-43; quiz following 343
16757971
J Clin Oncol. 2001 Feb 15;19(4):1195-206
11181686
Neuro Oncol. 2002 Jan;4(1):39-43
11772431
J Pediatr Hematol Oncol. 2003 May;25(5):372-8
12759623
Neuro Oncol. 2009 Feb;11(1):69-79
18772354
Clin Cancer Res. 2009 Jan 1;15(1):330-7
19118062
J Clin Oncol. 2004 Feb 15;22(4):610-6
14726505
Cancer Res. 2003 Aug 1;63(15):4342-6
12907602
Cancer. 2007 Oct 1;110(7):1542-50
17705175
J Neurooncol. 2006 Mar;77(1):89-94
16292488